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Background/aim: To investigate the biometric components and refractive errors in premature infants with or without retinopathy of
prematurity (ROP).
Materials and methods: Anterior chamber depth, lens thickness, vitreous length, and axial length were measured with an ultrasound
biometer. Cycloplegic refraction was performed by streak skiascopy. Infants with or without ROP were grouped according to
postmenstrual age at the time of ocular examination: Group 1, ≤33 weeks; Group 2, 34–37 weeks; Group 3, 38–41 weeks; Group 4,
42–45 weeks; Group 5, ≥46 weeks.
Results: The mean postnatal age of 894 infants (451 females and 443 males) was 8.7 ± 4.5 weeks, gestational age was 30.9 ± 2.8 weeks,
and birth weight was 1506 ± 484 g. In Group 2, the mean vitreous length and axial length of infants with ROP were significantly lower
than those of infants without ROP (P = 0.011, P = 0.001). The mean anterior chamber depth, lens thickness, spherical equivalent, and
astigmatism in all groups did not differ significantly among the infants with or without ROP (P > 0.05).
Conclusion: The anterior chamber depth, lens thickness, vitreous length, and axial length showed a linear growth throughout the
follow-up period. The maximum elongation was observed in vitreous length and axial length.
Key words: Biometry, infant, hyperopia, myopia, retinopathy of prematurity, retinoscopy

1. Introduction
Prematurity is by far the most frequent cause of neonatal
morbidity and mortality. Over the last 50 years, survival
rates for premature babies have dramatically increased.
In parallel with this improved survival, the incidence of
retinopathy of prematurity (ROP), refractive errors, and
ocular anomalies has also risen. Prematurely born children
are at increased risk of ocular morbidities such as myopia,
strabismus, and defective visual acuity (1–5).
Size of eyeball at birth, the neonatal period, and infancy
and the curvature of the cornea, lens characteristics,
and refractive errors are closely associated with physical
characteristics such as birth weight, gestational age, length,
and head circumference (6,7). The refractive errors among
humans depend on several ocular causes such as cataract,
corneal ectasia, and ROP. It has been demonstrated that
the presence of ROP leads to the development of myopia,
astigmatism, and anisometropia. There is a tendency
towards low myopia in premature infants (8–10).
The aim of this study is to examine prospectively
the ocular growth parameters and refractive status in
* Correspondence: ozdemirozdemir@yahoo.com
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premature infants with or without ROP during the early
months of infancy.
2. Materials and methods
2.1. Participants
Infants were enrolled in the study by routine screening
for ROP. Infants weighing 1500 g or less with a gestational
age of 32 weeks, and selected premature infants with an
unstable clinical progression, were included with the
recommendation of a pediatrician or neonatologist (11).
The exclusion criteria were the presence of congenital
anomalies in other parts of the body, congenital eye
abnormalities, unsuitable general conditions for an ocular
examination, ROP of stage 4 and higher, and previous
treatment applications such as laser photocoagulation
and/or intravitreal injections. The right eyes of the infants
were studied to obtain the results.
2.2. Refraction measurement
Thirty minutes after the administration of 1% topical
tropicamide twice at an interval of 10 min, cycloplegic
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refraction was performed just before fundus evaluation.
A pediatric lid speculum was placed gently between the
eyelids and refraction measurement was performed with
streak skiascopy (Welch Allyn Elite Retinoscope, Welch
Allyn Inc., USA) (12). Retinoscopy was performed at
approximately 67 cm, neutralizing each principal meridian
separately and then subtracting the empirically derived
1.5 D from the final spherical neutralizing lens. Spherical
equivalent and cylindrical power measurements were
recorded. Spherical equivalent was calculated as (spherical
equivalent = sphere + [cylinder / 2]).
2.3. ROP examination
For the funduscopic examination with scleral indentation,
after instillation of topical anesthetic 0.5% proparacaine
hydrochloride, a binocular indirect ophthalmoscope
(Heine Optotechnik, Germany) was used. ROP was
graded according to the international classification of
ROP (13). The first examination was scheduled between
4 and 6 postnatal weeks. Follow-up examinations for ROP
screening were planned at an interval of approximately 1
to 3 weeks according to the results of the retinal ﬁndings,
until normal vascularization proceeded to zone 3.
2.4. Biometry measurement
Biometry was measured with an ultrasound biometer
(Compact Touch Ultrasound System, France). An A-scan
probe was placed gently and perpendicularly on the
central cornea. Special attention was given to avoiding
any indentation of cornea. For the right eyes, the average
values of 5 measurements of anterior chamber depth, lens
thickness, and vitreous and axial length were recorded.
2.5. Statistical analysis
Birth weight, gestational age, sex, zone and stage of acute
ROP at the examination, refraction measurement, and
biometry measurement were recorded. These values were
compared between premature infants with or without
ROP. Infants were grouped according to postmenstrual
age at the time of ocular examination. Group 1 included
infants up to 33 weeks of age; Group 2 included 34, 35, 36,
and 37 weeks; Group 3 included 38, 39, 40, and 41 weeks;

Group 4 included 42, 43, 44, and 45 weeks; and Group 5
included infants of 46 weeks and above.
SPSS 16.0 (SPSS Inc., USA) was used for statistical
analyses. Data are reported as the mean ± standard
deviation (SD), frequency, and percentages. Initially, a
one-sample Kolmogorov–Smirnov test was performed
for determining normally distributed variables. Then,
as examples in the groups did not distribute normally,
nonparametric tests and the Mann–Whitney U test were
used for comparisons. Significance was defined as P < 0.05.
2.6. Statement of ethics
The research followed the tenets of the Declaration of
Helsinki, and informed consent was obtained from the
parents after explanation of the nature and possible
consequences of the study. The research was approved by
the local institutional review board.
3. Results
A total of 894 infants (451 females and 443 males) were
recruited for the study. Number, sex, mean postnatal age,
gestational age, and birth weight of groups are shown in
Tables 1 and 2. The gestational age of infants ranged from
23 to 36 weeks (mean: 30.9 ± 2.8 weeks), the postmenstrual
age of infants ranged from 28 to 51 weeks (mean: 39.6 ± 4.6
weeks), and the birth weight of infants ranged from 560 to
2670 g (mean: 1506 ± 484 g). Most infants were examined
between 38 and 41 postmenstrual weeks (Group 3). The
number of infants without ROP (527) was higher than the
number of infants with ROP (367). In infants with ROP, 4
infants developed zone 1 stage 1, 134 infants zone 2 stage
1, 17 infants zone 2 stage 2, 10 infants zone 2 stage 3, 193
infants zone 3 stage 1, 7 infants zone 3 stage 2, and 2 infants
zone 3 stage 3; as a result, 367 infants had developed ROP
at the examination time.
Table 3 shows the mean anterior chamber depth,
lens thickness, vitreous length, axial length, spherical
equivalent, and astigmatism of infants. Apart from Group
1, the mean anterior chamber depth of infants with
ROP was lower than in infants without ROP. However,

Table 1. The mean postmenstrual age of infants in the groups (SD: standard deviation, min: minimum, max:
maximum).
Groups

Postmenstrual age (weeks)

SD (weeks)

Min–max (weeks)

Group 1

31.3

1.5

28–33

Group 2

35.9

1.0

34–37

Group 3

39.3

1.1

38–41

Group 4

43.0

1.0

42–45

Group 5

47.9

1.6

46–51
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Table 2. Number, sex, mean postnatal age, gestational age, and birth weight of infants with or without ROP in groups (SD: standard
deviation, F: female, M: male, ROP–: infants without ROP, ROP+: infants with ROP).
Groups

Number

Sex

Mean postnatal
age ± SD (weeks)

Mean gestational
age ± SD (weeks)

Mean birth
weight ± SD (g)

Group 1

80

44 F, 36 M

4.6 ± 1.3

26.6 ± 1.9

985 ± 227

ROP–

42

23 F, 19 M

4.5 ± 0.6

27.3 ± 1.9

1036 ± 223

ROP+

38

21 F, 17 M

4.7 ± 1.8

26.0 ± 1.8

942 ± 214

Group 2

204

101 F, 103 M

5.3 ± 1.9

30.5 ± 1.9

1478 ± 395

ROP–

132

63 F, 69 M

4.8 ± 1.6

31.2 ± 1.5

1604 ± 365

ROP+

72

38 F, 34 M

6.3 ± 1.9

29.3 ± 1.9

1246 ± 339

314

156 F, 158 M

7.6 ± 2.7

31.7 ± 2.6

1631 ± 483

ROP–

202

98 F, 104 M

6.6 ± 2.3

32.6 ± 2.2

1776 ± 450

ROP+

112

58 F, 54 M

9.4 ± 2.5

30.0 ± 2.4

1369 ± 429

194

98 F, 96 M

11.4 ± 3.0

31.6 ± 2.7

1549 ± 475

ROP–

104

54 F, 50 M

10.3 ± 3.0

32.5 ± 2.7

1696 ± 504

ROP+

90

44 F, 46 M

12.6 ± 2.5

30.6 ± 2.3

1380 ± 375

Group 3

Group 4

Group 5

102

52 F, 50 M

16.7 ± 3.3

31.1 ± 2.9

1507 ± 542

ROP–

47

25 F, 22 M

15.7 ± 2.8

32.0 ± 2.4

1713 ± 498

ROP+

55

27 F, 28 M

17.6 ± 3.5

30.3 ± 3.0

1331 ± 519

894

451 F, 443 M

8.7 ± 4.5

30.9 ± 2.8

1506 ± 484

ROP–

527

263 F, 264 M

7.5 ± 3.9

31.6 ± 2.8

1644 ± 483

ROP+

367

188 F, 179 M

10.3 ± 4.7

29.8 ± 2.5

1308 ± 410

Total

Table 3. Comparison of the mean biometry components and refraction measurements of infants with or without ROP in groups. Data
are represented as mean ± SD (SD: standard deviation, ACD: anterior chamber depth, LT: lens thickness, VL: vitreous length, AL: axial
length, SphEq: spherical equivalent, Ast: astigmatism, D: diopter, ROP–: infants without retinopathy of prematurity, ROP+: infants with
retinopathy of prematurity, P: Mann–Whitney U test, *: statistically significant).
Groups
Group 1

Group 2

Group 3

Group 4

Group 5
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ACD (mm)

LT (mm)

VL (mm)

AL (mm)

SphEq (D)

Ast (D)

ROP–

2.10 ± 0.22

3.26 ± 0.37

9.08 ± 0.76

15.70 ± 0.42

0.8 ± 1.3

0.3 ± 0.3

ROP+

2.12 ± 0.35

3.11 ± 0.45

8.76 ± 0.82

15.42 ± 0.71

1.0 ± 0.9

0.5 ± 0.6

P

0.497

0.202

0.260

0.118

0.744

0.704

ROP–

2.26 ± 0.33

3.67 ± 0.48

10.40 ± 0.42

16.30 ± 0.34

1.8 ± 1.2

0.6 ± 0.5

ROP+

2.24 ± 0.51

3.57 ± 0.35

9.79 ± 1.04

15.99 ± 0.41

1.6 ± 1.2

0.6 ± 0.4

P

0.110

0.359

0.011*

0.001*

0.052

0.491

ROP–

2.18 ± 0.28

3.98 ± 0.35

10.76 ± 0.61

16.79 ± 0.65

2.2 ± 1.0

0.6 ± 0.4

ROP+

2.16 ± 0.51

4.08 ± 0.93

10.30 ± 1.55

16.67 ± 0.72

2.0 ± 1.2

0.6 ± 0.4

P

0.044

0.307

0.174

0.658

0.112

0.841

ROP–

2.31 ± 0.52

4.13 ± 0.48

10.93 ± 0.55

17.16 ± 0.61

2.6 ± 1.0

0.6 ± 0.4

ROP+

2.27 ± 0.56

4.14 ± 0.85

10.95 ± 0.45

16.94 ± 0.67

2.7 ± 1.2

0.6 ± 0.6

P

0.518

0.188

0.771

0.159

0.351

0.888

ROP–

2.71 ± 0.26

4.16 ± 0.49

11.44 ± 0.49

18.29 ± 0.75

3.0 ± 0.8

0.7 ± 0.3

ROP+

2.56 ± 0.31

3.94 ± 0.41

11.20 ± 0.83

17.94 ± 0.80

2.5 ± 1.3

0.9 ± 0.5

P

0.063

0.201

0.122

0.159

0.110

0.111
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length were 0.60 mm and 0.64 mm per month. The mean
spherical equivalent and astigmatism increased from 0.9
± 1.1 to 2.7 ± 1.1 D and from 0.4 ± 0.5 to 0.8 ± 0.5 D.
Their increase rates were 0.45 D and 0.08 D per month,
respectively (Figure 2).

the differences were not statistically significant (P >
0.05). The mean lens thickness of infants did not differ
significantly among groups (P > 0.05). In Group 2, the
mean vitreous length and axial length of infants with ROP
were significantly lower than in infants without ROP (P
= 0.011, P = 0.001, respectively). In the other groups, the
difference between mean vitreous length and axial length
among infants was not significant (P > 0.05). In addition,
the mean spherical equivalent and astigmatism did not
differ significantly in any of the groups (P > 0.05).
Anterior chamber depth, lens thickness, vitreous
length, and axial length showed a linear growth
throughout the follow-up period (Figure 1). The mean
anterior chamber depth grew from 2.11 ± 0.31 mm to 2.63
± 0.30 mm between the first and last examination time.
It increased by 0.13 mm per month. Similarly, the mean
lens thickness changed from 3.17 ± 0.43 mm to 4.03 ±
0.46 mm. The growth rate of the lens thickness was 0.21
mm per month. The mean vitreous length and the axial
length elongated from 8.88 ± 0.81 mm to 11.30 ± 0.71 mm
and from 15.52 ± 0.63 to 18.09 ± 0.79 mm, respectively.
In Groups 1 to 5, growth rates of vitreous length and axial
mm 20
18
16
14
12
10
8
6
4
2
0 Group 1

Anterior chamber depth (mm)
Lens thickness (mm)
Vitreous length (mm)
Axial length (mm)

2.11
3.17
8.88
15.52

4. Discussion
Evidence showed that vitreous length and axial length
differed between infants with or without ROP in Group 2 (34
to 37 postmenstrual weeks). In addition, infants with ROP
in Group 2 showed shorter posterior segments. Neither
the anterior chamber depth nor the lens thickness altered
in infants with or without ROP in the study population.
Maximum elongation was observed in vitreous length
and, as a result, in axial length during the study period.
The spherical equivalent developed correspondingly to
the growth of postmenstrual age. However, the increase of
astigmatism power was limited.
ROP is a disease affecting the growth of the eyeballs and
the development of refraction. ROP may lead to impaired
visual acuity and/or blindness in children. Therefore, it
is important to determine the dimensions of the globe

Anterior chamber depth (mm)
Lens thickness (mm)
Vitreous length (mm)
Axial length (mm)
Group 2
2.25
3.64
10.22
16.21

Group 3
2.18
4.01
10.64
16.76

Group 4
2.29
4.13
10.94
17.04

Group 5
2.63
4.03
11.3
18.09

Figure 1. The mean biometry components of the groups.
D 3
2.5

Spherical equivalent (D)
Astigmatism (D)

2
1.5
1
0.5
0
Spherical equivalent (D)
Astigmatism (D)

Group 1
0.94
0.46

Group 2
1.81
0.67

Group 3
2.15
0.62

Group 4
2.68
0.63

Group 5
2.79
0.81

Figure 2. The mean spherical equivalent and astigmatism of the groups.
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and measure the refractive errors for understanding this
disease and its effects (14,15). It has been revealed that
ROP is a risk factor for strabismus, visual impairments,
and abnormal refractive errors including anisometropia,
high myopia, hyperopia, or astigmatism. Changes in lens
thickness or in the anterior segment depth are associated
with high myopia and with a mechanism of altered anterior
segment development in ROP (16,17). Eyes of premature
infants with ROP have shallower anterior chambers,
shorter axial length, and more highly curved corneas (7).
Laws et al. studied a total of 496 readings from 171
infants between 32 and 41 weeks postconceptual age. They
found that mean axial length increased by 1.38 mm for the
left eye (15.27 to 16.65 mm) and by 1.35 mm for the right eye
between 32 and 41 weeks postconceptual age. During this
study period, the mean growth rate was 0.18 mm/week for
both eyes (18). These results are very close to the data in our
study. In our analyzed examination, the growth rate of axial
length was 0.64 mm per month; the axial length elongated
from 15.52 to 18.09 mm between 28 and 51 weeks. Similarly,
Cook et al. examined 136 premature babies longitudinally
between 32 and 52 weeks postmenstrual age and showed
that axial length grew linearly throughout the study period.
They reported that as the stage of ROP increased, the average
axial length and posterior segment length decreased.
Moreover, they found that average anterior chamber depth
and lens thickness did not vary significantly between stages
of ROP (7). Unlike the investigation of Cook et al., our
study included only 12 infants with stage 3 and excluded
infants with ROP at or above stage 4. We determined that
vitreous length and axial length differed significantly only
in Group 2 (34 to 37 postmenstrual weeks) among infants
with or without ROP. Although not statistically significant
in all groups, it is noteworthy that the axial length of infants
with ROP is shorter.
We previously investigated the axial length of 374 eyes in
187 premature infants at 40 weeks of mean postmenstrual
age and reported that there were no differences in axial
length between infants with and without ROP (19). In
the present study we achieved similar results, except for
infants between 34 and 37 weeks postmenstrual age. We
worked with more infants and analyzed a broader range of
postmenstrual ages between 28 and 51 weeks than in the
former study.
It is clear that the vitreous chamber was the most
prolonged part of the eye. It was elongated from 8.88 to
11.3 mm between 28 and 51 postmenstrual weeks. Hereby,
the axial length increased by 0.64 mm per month and
reached 18.09 mm at approximately 49 postmenstrual
weeks (the mean postmenstrual week of Group 5). When
examining the vitreous length and axial length of infants
with or without ROP, significant differences were seen
only between 34 and 37 postmenstrual weeks. We suggest
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that the elongation of the globe is affected by ROP disease
during this period. It may be related to the appearance of
the ROP disease after the fourth postnatal week.
The refractive status of premature infants differs
from that of full-term infants. The majority of changes
in refractive errors appear in the first year of life. It has
long been known that infants are usually hyperopic,
and refractive powers decrease during infancy and early
childhood. Studies of refractive development have shown
that the mean refractive error is around +2 D in newborns
(20). There is higher prevalence and variance of myopia
in preterm school children (21). The exact mechanism
of myopia related to ROP is unknown and may be due
to thickening of the lens or alteration of the corneal
curvature, elongation of the globe, or a combination of
all these factors (22,23). Despite the existing data on the
development of refraction in infancy and childhood, few
studies have documented the changes in refractive error
in the earliest measurable weeks of premature life (6,7,24).
Extremely preterm babies are recognized to be myopic,
and term babies are recognized to be hypermetropic
(24). It was demonstrated that refractive error changed
by 3 months of postmenstrual age, and stage 3 eyes had
less hypermetropia than other stages, with the difference
being greater in the treated eyes (7). In the present study,
there was no difference in the mean values of refractive
error between infants with or without ROP. The spherical
equivalent increased linearly during the follow-up period.
One of the limitations of this study was the use of
cycloplegic agents other than cyclopentolate or atropine
for cycloplegia. Cycloplegia is essential for measuring
the refractive error and eliminating any uncontrolled
accommodation in children (25). To avoid the side effects
of cyclopentolate, we preferred to use topical tropicamide
for cycloplegia. Tropicamide is a parasympatholytic drug.
The onset of action of the drug begins 15 to 30 min after
instillation. Its duration of action is 4 to 6 h, having the
shortest half-life of all drugs. Because it is eliminated
quickly from the body, it is ideal for children with
special needs and other instances of hypersensitivity to
cholinergic agents. Tropicamide has fewer side effects than
other cycloplegics (26–28). In addition, it does not require
long-term follow-up of the same patients. It is required to
evaluate infants from the preterm period until 1 year of
age. Further studies about the measurement of biometric
components in the developing eye may help clarify the
factors underlying the development of abnormal refractive
errors in infants with ROP.
In conclusion, prospectively examining the ocular
growth parameters, refractive statuses, and their relation
with ROP in premature infants during the early months
of infancy provides important information to clinicians
for understanding the growth of biometric variables and
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the development of refractive errors. Anterior chamber
depth, lens thickness, vitreous length, and axial length
showed linear growth throughout the follow-up period.
Between 34 and 37 postmenstrual weeks, the vitreous
length and axial length of infants with ROP were lower
than in infants without ROP. The maximum elongation

was observed in vitreous length and, as a result,
in axial length. The spherical equivalent increased
linearly during the follow-up period. However, the
increase of astigmatism power was slight. Moreover,
the refractive errors in premature infants with ROP
did not differ from those of infants without ROP.
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